Abstract
Humoral and cellular immune responses were analyzed with Fuenzalida-Palacios rabies vaccine associated with pGPL-Mc, polar glycopeptidolipids extracted from Mycobacterium chelonae, aiming at its use as adjuvant. These results were compared to those obtained with BCG, a well-known immunostimulator, under the same conditions. Rabies vaccine plus pGPL-Mc (2.5 mg/kg) induced a significant increase in serum neutralizing activity, in vitro lymphocyte proliferation (spontaneous, specific and mitogen stimulation) and delayed type hypersensibility. In addition, pGPL-Mc, as well as BCG, enhanced the vaccine potency. Our results support further studies to encourage the use of pGPL-Mc as an immunostimulator of veterinary vaccines, before consideration for human vaccines.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic* / adverse effects
-
Animals
-
Antibodies, Viral / biosynthesis
-
Antibodies, Viral / immunology
-
Antigens, Bacterial / adverse effects
-
Antigens, Bacterial / immunology*
-
BCG Vaccine / immunology
-
Chemical Phenomena
-
Chemistry, Physical
-
Female
-
Glycopeptides / adverse effects
-
Glycopeptides / immunology*
-
Humans
-
Hypersensitivity, Delayed / etiology
-
Immunity, Cellular
-
Interferons / biosynthesis
-
Lymphocyte Activation / immunology
-
Mice
-
Mice, Inbred BALB C
-
Mycobacterium chelonae / immunology*
-
Neutralization Tests
-
Rabies Vaccines / adverse effects
-
Rabies Vaccines / immunology*
-
Rabies virus / immunology*
-
Safety
-
Spleen / immunology
-
Thymus Gland / immunology
Substances
-
Adjuvants, Immunologic
-
Antibodies, Viral
-
Antigens, Bacterial
-
BCG Vaccine
-
Glycopeptides
-
Rabies Vaccines
-
Interferons